FrancophonIA/ELRC3.0 huggingface dataset:
English: Musculoskeletal and connective tissue disorders pain in extremity, myalgia, back pain, muscle spasms, arthralgia, muscle tightness, musculoskeletal stiffness musculoskeletal pain --
Estonian: Lihaste, luustiku ja sidekoe kahjustused valu jäsemetes, müalgia, seljavalu, lihasspasmid, artralgia, lihaspinge, lihasskeleti jäikus lihasskeleti valu --
English: Studies have not been performed to examine the effects of Fabrazyme on fertility.
Estonian: Fabrazyme'i mõju viljakusele ei ole uuritud.
English: Fabrazyme 35 mg powder for concentrate for solution for infusion Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride intravenous solution, from the infusion bag.
Estonian: Fabrazyme 35 mg infusioonilahuse kontsentraadi pulber Enne patsiendi jaoks vajaliku annuse Fabrazyme'i lahjendatud lahuse lisamist 0,9% naatriumkloriidi intravenoossele lahusele on infusioonikotist soovitav eelnevalt eemaldada sama kogus füsioloogilist lahust.
English: Respiratory, thoracic and mediastinal disorders dyspnoea, nasal congestion, throat tightness, wheezing, cough, dyspnoea exacerbated bronchospasm, pharyngolaryngeal pain, rhinnorhoea, tachypnoea, upper respiratory tract congestion hypoxia
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired düspnoe, ninakinnisus, pigistustunne kurgus, köha, vilistav hingeldus, ägenenud düspnoe bronhospasm, farüngolarüngaalne valu, rinorröa, tahhüpnoe, ülemiste hingamisteede turse hüpoksia
English: Sanofi S.p.A. Tel: +39 02 39394275
Estonian: Tel: +39 02 39394275
English: The educational material for patients should include information on the following key elements: - The prescribing physician may decide that Fabrazyme may be administered at home.
Estonian: - Ravimit välja kirjutav arst võib otsustada, et Fabrazyme'i võib manustada kodus.
English: • musculoskeletal stiffness
Estonian: • lihasskeleti jäikus
English: Another double-blind, placebo-controlled study of 82 patients was performed to determine whether Fabrazyme would reduce the rate of occurrence of renal, cardiac, or cerebrovascular disease or death.
Estonian: Eesmärgiga kindlaks teha, kas Fabrazyme vähendab renaalsete, kardiaalsete või tserebrovaskulaarsete komplikatsioonide riski või suremust, viidi läbi teine, 82 patsienti hõlmav, topeltpime, platseebokontrolliga uuring.
English: General disorders and administration site conditions chills, pyrexia, feeling cold fatigue, chest discomfort, feeling hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia feeling hot and cold, influenza-like illness, infusion site pain, infusion site reaction, injection site thrombosis, malaise, oedema
Estonian: Üldised häired ja manustamiskoha reaktsioonid külmavärinad, palavik, külmatunne ebamugavustunne rindkeres, palavustunne, perifeerne turse, valu, asteenia, valu rindkeres, näo turse, hüpertermia kuuma- ja külmatunne, gripitaoline haigus, valu infusioonipiirkonnas, süstekoha reaktsioon, süstekoha tromboos, halb enesetunne, turse
English: Fabrazyme 5 mg powder for concentrate for solution for infusion Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride intravenous solution, from the infusion bag.
Estonian: Fabrazyme 5 mg infusioonilahuse kontsentraadi pulber Enne patsiendi jaoks vajaliku annuse Fabrazyme'i lahjendatud lahuse lisamist 0,9% naatriumkloriidi intravenoossele lahusele on infusioonikotist soovitav eelnevalt eemaldada sama kogus füsioloogilist lahust.
English: 10 vials of powder for concentrate for solution for infusion.
Estonian: 10 viaali infusioonilahuse kontsentraadi pulbriga.
English: Fabrazyme 5 mg powder for concentrate for solution for infusion Fabrazyme 5 mg is supplied in clear Type I glass 5 ml vials.
Estonian: Fabrazyme 5 mg infusioonilahuse kontsentraadi pulber Fabrazyme 5 mg on läbipaistvast, I tüüpi klaasist 5 ml viaalides.
English: The level of support required for home infusion will be discussed and agreed by the patient and/or caregiver with the prescribing physician.
Estonian: Patsient ja/või hooldaja arutavad ja lepivad ravimit välja kirjutava arstiga kokku, millist abi on vaja ravimi koduseks infusiooniks.
English: • tinnitus
Estonian: • punetus
English: 5 vials of powder for concentrate for solution for infusion.
Estonian: 5 viaali infusioonilahuse kontsentraadi pulbriga.
English: Reconstitute each vial of Fabrazyme 35 mg with 7.2 ml water for injections.
Estonian: Lahustage iga Fabrazyme'i 35 mg viaali sisu 7,2 ml süsteveega.
English: Fabrazyme 5 mg powder for concentrate for solution for infusion Reconstitute each vial of Fabrazyme 5 mg with 1.1 ml water for injections.
Estonian: Fabrazyme 5 mg infusioonilahuse kontsentraadi pulber Lahustage iga Fabrazyme 5 mg viaali sisu 1,1 ml süsteveega.
English: Fabrazyme 35 mg powder for concentrate for solution for infusion Each vial of Fabrazyme contains a nominal value of 35 mg of agalsidase beta.
Estonian: Fabrazyme 35 mg infusioonilahuse kontsentraadi pulber Üks Fabrazyme'i viaal sisaldab nominaalkogusena 35 mg beetaagalsidaasi.
English: No data are available in children 0 to 4 years No dose adjustment is necessary for children 8-16 years
Estonian: Puuduvad andmed laste kohta vanuses 0…4 aastat.
English: • malaise
Estonian: • väsimus
English: Sodium phosphate monobasic, monohydrate Sodium phosphate dibasic, heptahydrate.
Estonian: Abiained: mannitool ühealuseline naatriumfosfaat monohüdraat kahealuseline naatriumfosfaat heptahüdraat.
English: Contents of the pack and other information
Estonian: Kuidas Fabrazyme'i säilitada Pakendi sisu ja muu teave
English: Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of patients (see section
Estonian: Väikesel arvul patsientidel on teatatud reaktsioonidest, mis viitavad otsesele (I tüüpi) ülitundlikkusele (vt lõik 4.4).
English: • pallor
Estonian: • lööve
English: - The need to seek urgent treatment in the event of failure to gain venous access or if there is a lack of efficacy - The need to keep a diary to document each treatment received at home and to bring it at each visit
Estonian: - Iga koduse ravi dokumenteerimiseks tuleb pidada päevikut ja see tuleb igale visiidile kaasa võtta.
English: Not known (frequency cannot be estimated from the available data):
Estonian: Teadmata (ei saa hinnata olemasolevate andmete alusel) • madalam hapnikutase veres • veresoonte põletik
English: Fabrazyme 5 mg powder for concentrate for solution for infusion Each vial of Fabrazyme contains a nominal value of 5 mg of agalsidase beta.
Estonian: Fabrazyme 5 mg infusioonilahuse kontsentraadi pulber Üks Fabrazyme'i viaal sisaldab nominaalkogusena 5 mg beetaagalsidaasi.
English: Fabrazyme 35 mg powder for concentrate for solution for infusion agalsidase beta
Estonian: Fabrazyme, 35 mg infusioonilahuse kontsentraadi pulber agalsidasum beta
English: Reconstitute each vial of Fabrazyme 5 mg with 1.1 ml water for injections.
Estonian: Lahustage iga Fabrazyme'i 5 mg viaali sisu 1,1 ml süsteveega.
English: Agalsidase beta may be excreted in milk.
Estonian: Beetaagalsidaas võib erituda rinnapiima.
English: • chest discomfort
Estonian: • ebamugavustunne maos
English: • musculoskeletal pain
Estonian: • lihasskeleti valu
English: • lethargy
Estonian: • kurguvalu
English: • pain at the extremities
Estonian: • valu jäsemetes
English: Fabrazyme 5 mg powder for concentrate for solution for infusion agalsidase beta
Estonian: Fabrazyme 5 mg infusioonilahuse kontsentraadi pulber agalsidasum beta
English: • ear swelling
Estonian: • lihaspinge
English: If you experience a reaction like this, you should tell your doctor immediately.
Estonian: Kui teil tekib selline kõrvaltoime, konsulteerige otsekohe oma raviarstiga.
English: Ear and labyrinth disorders tinnitus, vertigo auricular swelling, ear pain
Estonian: Kõrva ja labürindi kahjustused tinnitus, peapööritus kõrvade turse, kõrvavalu
English: Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride intravenous solution, from the infusion bag.
Estonian: Enne patsiendi jaoks vajaliku annuse Fabrazyme'i lahjendatud lahuse lisamist 0,9% naatriumkloriidi intravenoossele lahusele on infusioonikotist soovitav eelnevalt eemaldada sama kogus füsioloogilist lahust.
English: Cardiac Disorders tachycardia, palpitations, bradycardia sinus bradycardia --
Estonian: tahhükardia, südamepekslemine, bradükardia siinusbradükardia --
English: Skin and subcutaneous tissue disorders pruritus, urticaria, rash, erythema, pruritus generalized, angioneurotic oedema, swelling face, rash maculo-papular livedo reticularis, rash erythematous, rash pruritic, skin discolouration, skin discomfort leukocytoclastic vasculitis
Estonian: Naha ja nahaaluskoe kahjustused sügelemine, nõgestõbi, lööve, erüteem, generaliseerunud sügelemine, angioneurootiline ödeem, makulopapulaarne lööve, näo paistetus võrkjas sinikus, erütematoosne lööve, sügelev lööve, nahakahvatus, ebamugavustunne nahal leukotsütoklastilin e vaskuliit
English: • nasopharyngitis
Estonian: • seljavalu
English: • itching eyes
Estonian: • silmade sügelemine
English: The educational material for healthcare professionals should include information on the following key elements: - Guidance regarding patient evaluation and selection and organisational requirements for home infusion.
Estonian: - Patsientide hindamise ja valimise ning koduse infusiooni korraldamise juhised.
English: • dizziness
Estonian: • näoturse
English: 1 vial of powder for concentrate for solution for infusion.
Estonian: 1 viaal infusioonilahuse kontsentraadi pulbriga.
English: • pain
Estonian: • turse
English: In another study with 30 paediatric patients with available pharmacokinetics data, aged 5 to 18 years, treated with two lower dose regimens of 0.5 mg/kg every 2 weeks and 1.0 mg/kg every 4 weeks, mean CL was 4.6 and 2.3 ml/min/kg, respectively, mean Vss was 0.27 and 0.22 l/kg, respectively, and mean elimination half-life was 88 and 107 minutes, respectively.
Estonian: Teises uuringus raviti 30 last vanuses 5…18 aastat, kelle kohta on olemas farmakokineetika andmed, väiksemate annustega, 0,5 mg/kg iga 2 nädala järel ja 1,0 mg/kg iga 4 nädala järel.
English: • nasal congestion
Estonian: • ebamugavustunne nahal
English: • Periodic safety update reports (PSURs)
Estonian: MUUD TINGIMUSED JA NÕUDED MÜÜGILOALE • Perioodilised ohutusaruanded
English: • palpitations
Estonian: • lihasspasmid
English: • burning sensation
Estonian: • sügelev lööve
English: • oedema
Estonian: • unisus
English: • redness
Estonian: • sügelus
English: Both cases resolved.
Estonian: Mõlemad juhud lahenesid.
English: Older people (≥ 65 years)
Estonian: Eakad (≥65 aasta)
English: A summary of results is presented in Table 3.
Estonian: Tulemuste kokkuvõte on esitatud tabelis 3.
English: This will help to prevent dehydration.
Estonian: See aitab vältida dehüdratsiooni.
English: Tell your dentist immediately if you experience such symptoms.
Estonian: Teavitage oma hambaarsti kohe, kui märkate selliseid nähtusid.
English: The duration of the trial was one year.
Estonian: Uuring kestis ühe aasta.
English: While on treatment, these patients should avoid invasive dental procedures if possible.
Estonian: Edasise ravi ajal peaksid need patsiendid võimalusel hoiduma invasiivsetest dentaalsetest protseduuridest.
English: If the disease is not treated, bones may become deformed and painful, and may break.
Estonian: Kui haigust ei ravita, võivad luud muutuda deformeerunuks ja valulikuks ning murduda.
English: No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects.
Estonian: Annuse kohaldamine ei ole vajalik, sest ravimi biosaadavus, jaotumine ja eliminatsioon on eakatel ja noorematel patsientidel sarnane.
English: Component of a multipack, can't be sold separately.
Estonian: Hulgipakendi osa, ei müüda eraldi.
English: Clinical efficacy in men
Estonian: Kliiniline efektiivsus meestel
English: The educational programme contains the following:
Estonian: Õpetuslik info sisaldab järgmist:
English: The frequency of hypocalcaemia was much lower following subsequent infusions.
Estonian: Hüpokaltseemia sagedus oli palju väiksem peale järgnevaid infusioone.
English: Many of the reported cases have been associated with dental procedures such as tooth extraction.
Estonian: Paljud juhud on seotud dentaalsete protseduuridega, näiteks hambaekstraktsioon.
English: • in post-menopausal women
Estonian: • postmenopausis naistel
English: INFORMATION FOR THE HEALTHCARE PROFESSIONAL
Estonian: INFORMATSIOON TERVISHOIUTÖÖTAJALE
English: This corresponds to a 28% reduction in the risk of all cause mortality (p=0.01).
Estonian: See vastab misiganes põhjusega surmariski vähenemisele 28% võrra (p=0,01).
English: Not known** Renal impairment.
Estonian: Teadmata** Neerukahjustus.
English: Frequency categories are defined using the following convention: very common (≥1/10); common
Estonian: Esinemissageduse kategooriad on esitatud järgmise konventsiooni kohaselt: väga sage (≥1/10);
English: All clinical fractures were verified based on the radiographic and/or clinical evidence.
Estonian: Kõigi kliiniliste luumurdude diagnoos põhines radioloogilisel ja/või kliinilisel leiul.
English: Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions.
Estonian: Kõrvaltoimed on väga sagedased pärast esimest infusiooni (esinedes rohkem kui 30% patsientidest), kuid järgnevate infusioonidega muutuvad vähem sagedaseks.
English: Follow carefully all instructions given to you by your doctor or nurse.
Estonian: Järgige hoolikalt kõiki Teie arsti või meditsiiniõe poolt antud juhiseid.
English: The following information is intended for healthcare professionals only:
Estonian: Järgnev teave on ainult meditsiinipersonalile või tervishoiutöötajatele :
English: The infusion time must not be less than 15 minutes.
Estonian: Infusiooni aeg ei tohi olla vähem kui 15 minutit.
English: Osteoporosis could also occur in men and women because of the long term use of steroids, which can affect the strength of bones.
Estonian: Osteoporoos võib meestel ja naistel tekkida ka hormoonide pikaajalise kasutamise tõttu, mis võib mõjutada luude tugevust.
English: During this entire time period bone turnover markers were within the pre-menopausal range at the end of each year.
Estonian: Kogu selle aja jooksul olid luuainevahetuse markerid iga aasta lõpus premenopausile iseloomulikus vahemikus.
English: Repeat dosing did not lead to further reduction of bone turnover markers.
Estonian: Korduv annustamine ei viinud luuainevahetuse markerite edasise languseni.
English: The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race or body weight.
Estonian: Organismi kogukliirens on 5,04 ± 2,5 l/h, sõltuvalt annusest ning ei sõltu soost, east, rassist või kehakaalust.
English: Your doctor will let you know when to return for your next dose.
Estonian: Teie arst ütleb teile, millal järgmise annuse saamiseks uuesti tema juurde pöörduda.
English: Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Estonian: Enne ravimi kasutamist, lugege hoolikalt infolehte, sest siin on teile vajalikku teavet.
English: The majority of patients continued to receive glucocorticoids for the one year duration of the trial.
Estonian: Enamus patsiente sai jätkuvalt glükokortikoide uuringu üheaastase kestuse jooksul.
English: Summary of vertebral fracture efficacy at 12, 24 and 36 months
Estonian: Tabel 2 Kokkuvõte toimest lülimurdudele 12, 24 ja 36 kuu möödudes Tulemusnäitaja
English: Histomorphometric analysis showed a 63% reduction in bone turnover.
Estonian: Histomorfomeetriline analüüs näitas luuainevahetuse 63% vähenemist.
English: The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of zoledronic acid on an individual patient basis, particularly after 5 or more years of use.
Estonian: Ravi jätkamise vajadust tuleb taashinnata perioodiliselt kaaludes võimalikke zoledroonhappe riske ja kasu individuaalsetele patsientidele, eriti viie või enama kasutusaasta järel.
English: It is normal that old bone is removed and is replaced with new bone material.
Estonian: Tavaliselt vana luu eemaldatakse ja see asendatakse uuega.
English: Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.
Estonian: Võtke ühendust oma arstiga, kui tunnete valu, nõrkust või ebamugavustunnet reies, puusas või kubemes, kuna see võib olla võimaliku reieluumurru varajane tunnus.
English: The majority of these reactions were mild to moderate and resolved within three days of the event onset.
Estonian: Enamik nendest olid kerged kuni mõõdukad ja lahenesid kolme päeva jooksul alates nähtude tekkest.
English: Five of the 6 patients had SAP within the normal range at month 6 (Last Observation Carried Forward, LOCF).
Estonian: Kuuest patsiendist viiel esines 6 kuul SAP normaalvahemikus (Viimane Läbi Viidud Vaatlus, VLVV).
English: Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker.
Estonian: Paljudel osteoporoosi põdevatel patsientidel ei ole ühtki sümptomit, kuid neil on siiski luumurdude tekke risk, kuna osteoporoosi tõttu on nende luud nõrgemad.
English: The risk reduction was 51% in bisphosphonate-naïve patients and 42% in patients allowed to take concomitant osteoporosis therapy.
Estonian: Riski vähenemine oli 51% bisfosfonaat-ravi mittesaavatel patsientidel ja 42% patsientidel, kellel oli lubatud samaaegselt võtta osteoporoosi ravi.
English: It is important to take calcium and vitamin D supplements (for example tablets) as directed by your doctor.
Estonian: Oluline on kasutada kaltsiumi ja D-vitamiini preparaate (näiteks tablette) vastavalt arsti soovitustele.
English: Common (may affect up to 1 in 10 people)
Estonian: Sagedased (võivad tekkida kuni 1 inimesel 10-st)
English: • Physician educational material
Estonian: • Arsti õppematerjal
English: The primary efficacy variable was the incidence of clinical fractures over the duration of the study.
Estonian: Esmane efektiivsusnäitaja oli kliiniliste luumurdude esinemissagedus uuringuperioodi jooksul.
English: • in adult men at increased risk of fracture.
Estonian: • täiskasvanud meestel kellel on suurenenud luumurdude tekke risk.
English: Clinical experience with acute overdose is limited.
Estonian: Kliinilised kogemused üleannustamise korral on limiteeritud.
English: Single and multiple 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients yielded the following pharmacokinetic data, which were found to be dose independent.
Estonian: Zoledroonhappe annuste 2, 4, 8 ja 16 mg ühekordse ja korduva 5- ja 15-minutilise infusiooni manustamisel 64 patsiendile saadi järgmised farmakokineetilised andmed, mis osutusid annusest mittesõltuvaks.
English: Since zoledronic acid is not metabolised in humans and the substance was found to have little or no capacity as a direct-acting and/or irreversible metabolism-dependent inhibitor of P450 enzymes, zoledronic acid is unlikely to reduce the metabolic clearance of substances which are metabolised via the cytochrome P450 enzyme systems.
Estonian: Kuna zoledroonhape inimesel ei metaboliseeru ja aine leiti olevat ensüüm P450 suhtes vähese või olematu toimega, otsetoimiv ja/või pöördumatu metabolismist-sõltuv inhibiitor, siis zoledroonhape tõenäoliselt ei vähenda metaboolset kliirensit ainetel, mis metaboliseeruvad tsütokroom P450 ensüümsüsteemi kaudu.
English: • A single dose of zoledronic acid should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Estonian: • Zoledroonhappe ühekordne annus ei tohi ületada 5 mg ning infusiooni kestus peab olema vähemalt 15 minuti (vt lõik 4.2).
English: Zoledronic acid significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one year timepoint (see Table 2).
Estonian: Zoledroonhape vähendas oluliselt ühe või enama uue lülimurru esinemissagedust kolme aasta jooksul ning juba pärast üheaastast ravi (vt tabel 2).
English: Renal impairment has been observed in patients after a single administration.
Estonian: Neerufunktsiooni halvenemist on patsientidel täheldatud ka pärast ühekordset manustamist.
English: Other medicines and Zoledronic acid Teva Generics Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Estonian: Muud ravimid ja Zoledronic acid Teva Generics Teatage oma arstile, apteekrile või meditsiiniõele, kui te kasutate või olete hiljuti kasutanud mis tahes muid ravimeid.
English: Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category.
Estonian: Tabelis 1 on kõrvaltoimed esitatud MedDRA-süsteemi organklasside ja esinemissageduse kategooriate järgi.
English: Uncommon Hypertension, flushing Not known** Hypotension (some of the patients had underlying risk factors)
Estonian: Teadmata** Hüpotensioon (mõnedel olemasolevate riskifaktoritega patsientidel)
English: Zoledronic acid Teva Generics is not recommended for anyone under 18 years of age.
Estonian: Zoledronic acid Teva Generics'it ei soovitata alla 18 aastastele isikutele.
English: EXP After opening: 24 hours at 2°C - 8°C
Estonian: Pärast avamist: 24 tundi temperatuuril 2°C…8°C.
English: The highest non-lethal single intravenous dose was 10 mg/kg body weight in mice and 0.6 mg/kg in rats.
Estonian: Suurim mitte-letaalne ühekordne intravenoosne annus hiirtel oli 10 mg/kg kehakaalu kohta ja rottidel 0,6 mg/kg.
English: Swelling and/or pain at the infusion site may occur.
Estonian: Turse ja/või valu infusioonikohas.
English: All cause mortality was 10% (101 patients) in the zoledronic acid-treated group compared to 13% (141 patients) in the placebo group.
Estonian: Misiganes põhjusega suremus oli 10% (101 patsienti) zoledroonhappe grupis võrreldes 13%-ga (141 patsienti) platseebo-grupis.
English: Over the first 24 hours, 39 ± 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue.
Estonian: Esimese 24 tunni möödudes leidub 39 ± 16% manustatud annusest uriinis, allesjäänud osa seondub luukoega.
English: Your doctor, pharmacist or nurse knows how to store Zoledronic acid Teva Generics properly.
Estonian: Teie arst, apteeker või meditsiiniõde teab, kuidas Zoledronic acid Teva Generics'it õigesti säilitada.
English: Many of these patients had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries.
Estonian: Paljudel neist patsientidest on esinenud lokaalse infektsiooni tunnused, kaasa arvatud osteomüeliit ning enamik neist juhtudest on tekkinud vähihaigetel hambaekstraktsiooni või muude lõualuul teostatud kirurgiliste protseduuride järgselt.
English: The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid Teva Generics.
Estonian: Enamik kõrvaltoimeid nagu palavik ja külmavärinad, valu lihastes ja liigestes ja peavalu tekivad esimese kolme päeva jooksul peale Zoledronic acid Teva Generics'i manustamist.
English: In the three-year osteoporosis study standing height was measured annually using a stadiometer.
Estonian: Kolmeaastases osteoporoosi uuringus mõõdeti seisvas asendis pikkust kord aastas stadiomeetri abil.
English: Uncommon (may affect up to 1 in 100 people) Skin reactions such as redness.
Estonian: Aeg-ajalt esinevad (võivad tekkida kuni 1 inimesel 100-st) Naha reaktsioonid, nagu punetus.